Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab | Zendy

Bahadır Berktaş | Zendy; Adem Koyuncu | Zendy

Open Access

Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab

Author(s) -

Bahadır Berktaş,

Adem Koyuncu

Publication year - 2022

Publication title -

american journal of tropical medicine and hygiene

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.015

H-Index - 151

eISSN - 1476-1645

pISSN - 0002-9637

DOI - 10.4269/ajtmh.21-1010

Subject(s) - covid-19 , rituximab , medicine , pneumonia , mantle cell lymphoma , virology , antibody , viral pneumonia , immunology , betacoronavirus , lymphoma , pathology , outbreak , infectious disease (medical specialty) , disease

. Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID-19, mantle cell lymphoma, and rituximab-associated immunodeficiency. His COVID-19 clinical course was severe, unremitting, prolonged, and with frequent acute exacerbations requiring hospitalization. Viral shedding and failure to develop anti-severe acute respiratory syndrome coronavirus 2 antibodies continued for at least 6 months.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research